British pharma giant GSK said Tuesday that it will withdraw its blood cancer drug Blenrep from the U.S. market, following a request from the Food and Drug Administration.
Blenrep’s removal is another sign that U.S. regulators are taking a more aggressive stance toward cancer drugs approved based on preliminary evidence of efficacy.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
